| Title: |
Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis |
| Authors: |
Areej S. Albawa’neh; Mais N. Alqasrawi; Zeina N. Al-Mahayri; Amal Albawaana; Gamila Ahmed; Rami H. Al-Rifai; Bassam R. Ali |
| Source: |
Annals of Medicine, Vol 57, Iss 1 (2025) |
| Publisher Information: |
Taylor & Francis Group, 2025. |
| Publication Year: |
2025 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
Statins; ezetimibe; T2DM; diabetes mellitus; lipids; Medicine |
| Description: |
Background Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain.Objective This systematic review evaluated moderate-intensity statin plus ezetimibe dual therapy versus high-intensity statin monotherapy for NO-T2DM risk.Methods Five databases were searched to identify eligible studies. Random-effects meta-analyses generated pooled relative risks (RR) quantifying the effect of ezetimibe plus moderate-intensity statins on NO-T2DM. The Attributable Risk Fraction (ARF) was quantified utilizing the pooled estimate.Results Ten observational studies and four clinical trials were included. In four cohort studies, ezetimibe plus moderate-intensity statin compared to high-intensity statin monotherapy was significantly linked to 18% reduced risk of NO-T2DM (pooled RR: 0.82; 95% CI: 0.77–0.87; I2 = 0.0%; p < 0.001). In three methodologically similar studies, compared to moderate-intensity statin monotherapy, adding ezetimibe to moderate-intensity statin dual therapy showed non-statistically (p > 0.05) significant 4% increased risk of NO-T2DM development (pooled RR: 1.04; 95% CI: 0.94–1.14, I2= 0.0%). Compared with patients receiving high-intensity statin therapy, 22% of NO-T2DM cases could potentially be averted with dual therapy (moderate-intensity statin plus ezetimibe). In four studies involving 5,072 patients on high-intensity statins who developed NO-T2DM, 1,115 patients (812–1,420) could have been prevented with ezetimibe plus moderate-intensity statin dual therapy.Conclusion Incorporating ezetimibe with moderate-intensity statins, rather than relying solely on high-intensity statins, may reduce the risk of NO-T2DM in patients with dyslipidemia and elevated cardiovascular disease risk.Prospero Registration number CRD42024518630. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1365-2060; 0785-3890 |
| Relation: |
https://doaj.org/toc/0785-3890; https://doaj.org/toc/1365-2060 |
| DOI: |
10.1080/07853890.2025.2594355 |
| Access URL: |
https://doaj.org/article/b5dbcdf2f8314485933db0dbb8aa9bb0 |
| Accession Number: |
edsdoj.b5dbcdf2f8314485933db0dbb8aa9bb0 |
| Database: |
Directory of Open Access Journals |